#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating women with Long COVID should assess stress levels and cannabis use patterns, as both appear to elevate cortisol and may exacerbate symptom severity. Cannabis use in Long COVID patients could counterintuitively worsen the underlying neuroendocrine dysregulation driving persistent symptoms, making it an important factor to address in treatment planning. Understanding this relationship helps clinicians provide more targeted counseling about cannabis risks for this vulnerable population rather than assuming it provides symptomatic relief.
A recent study examining stress biomarkers in women with Long COVID found that psychological stress significantly correlates with persistent symptom severity, with cortisol dysregulation emerging as a measurable physiological marker. Notably, the research also identified that frequent cannabis users demonstrated elevated morning cortisol levels, suggesting that regular cannabis use may alter the hypothalamic-pituitary-adrenal axis function. This finding is clinically relevant for Long COVID patients who might consider cannabis as a symptom management strategy, as the stress-modulating benefits they seek could paradoxically be undermined by cortisol elevation. For physicians managing Long COVID in female patients, assessing both psychological stress and substance use patterns becomes important when evaluating HPA axis dysfunction and treatment response. Clinicians should counsel Long COVID patients that while cannabis is sometimes used for symptom relief, frequent use may worsen the underlying stress-related pathophysiology they are trying to address. Patients considering cannabis for Long COVID symptoms should discuss stress management alternatives and cortisol monitoring with their healthcare providers to optimize treatment outcomes.
“The stress-Long COVID connection is clinically meaningful and well-documented, but we need to be cautious about cannabis as a stress management tool here. The early signals about cannabis and cortisol regulation are worth watching, though the current evidence is preliminary, and we don’t yet have sufficient human trials to guide patients toward cannabis as a primary intervention for Long COVID-related stress.”
💚 While the relationship between cannabis use, stress physiology, and post-viral syndromes like Long COVID remains incompletely characterized, emerging evidence suggests that cannabis—particularly frequent use—may paradoxically elevate morning cortisol levels rather than providing the stress relief many patients seek, a finding that warrants attention given that stress is a documented contributor to Long COVID symptoms in women. Clinicians should recognize that patients with Long COVID may turn to cannabis for symptom management or anxiety relief, yet this strategy could potentially perpetuate or worsen the underlying neuroendocrine dysregulation that characterizes post-viral illness. Important caveats include the small sample sizes in cannabis pharmacology studies, individual variation in cannabinoid metabolism, and the possibility that cortisol elevation might reflect reverse causality or confounding by unmeasured factors such as sleep quality or concurrent stimulant use. When counseling women with Long COVID who use or are considering
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
